key: cord-1014234-fl419oof
authors: Chen, Bin Bin; Liu, Meng Li; Huang, Cheng Zhi
title: Current diagnostic and therapeutic strategies for COVID-19
date: 2021-01-13
journal: J Pharm Anal
DOI: 10.1016/j.jpha.2020.12.001
sha: 04dfb0de8b1e0ac51d0ed672652079cb7780ae62
doc_id: 1014234
cord_uid: fl419oof

The outbreak and spread of the novel coronavirus disease 2019 (COVID-19) with pandemic features, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have greatly threatened global public health. Given the perniciousness of COVID-19 pandemic, acquiring a deeper understanding of this viral illness is critical for the development of new vaccines and therapeutic options. In this review, we introduce the systematic evolution of coronaviruses and the structural characteristics of SARS-CoV-2. We also summarize the current diagnostic tools and therapeutic strategies for COVID-19.

The outbreak and spread of the novel coronavirus disease 2019 (COVID- 19) represents the most serious threat to global public health [1] [2] [3] [4] [5] . According to the World Health Organization (WHO), this disease was designated as a "public health emergency of international concern" on January 30, 2020. The corresponding virus was officially designated as 2019-nCoV by the Chinese Centers for Disease Control and Prevention, and later revised to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to a good sequence homology towards SARS-CoV genome [6] .

Genomic sequencing demonstrated that SARS-CoV-2 was 96.2% identical to a bat coronavirus and shared a 79.5% sequence similarity to SARS-CoV, indicating that J o u r n a l P r e -p r o o f this virus is most likely originated from bats [7] .

COVID-19 has become a major concern globally, with over 57 million confirmed cases and 1.37 million lives lost as of November 20, 2020 [8] . Moreover, millions of people's lives are at great risk because COVID-19 can be easily transmitted through direct contact with an infected person or indirect exposure to contaminated items [8] .

Health officials have approved some evidences of a transmission chain with four "generations", and proposed a sustained human-to-human transmission [9] . It has been speculated that a person infected with SARS-CoV-2 may infect more than three healthy individuals (the average reproductive number is approximately 3.28) [10] .

COVID-19 also has a major impact on the global economy and affected the day to day life of individuals. Businesses have shut down, schools have been suspended and stores have closed as a result of this disease. Therefore, COVID-19 will likely continue to become a global health challenge and have far-reaching economic impact if no control measures are in place [11] .

The development of diagnostics and therapeutics is in progress, but there is currently no vaccine or antiviral drug for the treatment of COVID-19. Diagnostic tools have a crucial role in the battle against COVID-19, which allow for the rapid implementation of control measures to suppress SARS-CoV-2 transmission via case identification, contact tracing, and isolation of positive cases [12] . The mainstay for the clinical management of COVID-19 patients is symptomatic treatment instead of curative treatment, where critically ill patients are treated with ventilatory support in the intensive care unit [13] . Other common treatment strategies include antiviral therapy, antibiotic therapy, immunomodulating therapy [14] , and so on. In this review, we first introduce the systematic evolution of coronaviruses (CoVs) and the structural characteristics of SARS-CoV-2. We then focus on known diagnostic tools and strategies for detecting SARS-CoV-2 in order to suppress its spread. Finally, we discuss current therapeutic methods, potential drugs, and vaccines. The overall intent of this review is to provide diagnostic and treatment strategies for dealing with COVID-19 pandemic through a summary of current findings. 

CoVs are types of RNA viruses with an enveloped, positive-strand, and single-stranded genome. They belong to the family Coronaviridae, the subfamily Orthocoronavirinae, and the order Nidovirales [15, 16] . The 5'-terminal and 3'-terminal of CoV genome have a methylated cap structure and a poly(A) tail, respectively, and the sizes vary from 27 kb to 32 kb (the largest known RNA virus genome) [17] . CoVs only infect vertebrates and the symptoms are similar to many human and animal diseases, such as those of the respiratory tract, digestive tract, and nervous system [18, 19] .

Based on the phylogenetic tree, CoVs are classified into 4 genera: alpha-, beta-, delta-and gamma-coronaviruses (α-, β-, δand γ-CoVs, respectively), of which β-CoV is further subclassified into 4 independent subgroups: β-CoV A, B, C and D ( Figure 1 ) [20] . Among them, both α-CoV and β-CoV usually infect humans and mammals, while δ-CoV and γ-CoV mainly infect birds [21] . To date, seven kinds of Human CoVs, including HCoV-229E, -HKU1, -NL63 and -OC43, often cause mild-to-moderate upper respiratory tract infections. With an apparent seasonality, infection from common human CoVs generally occurs in the winter and spring. The incubation period is about two-to-five days, during which time others are more prone to infection or being "vulnerable" if they are exposed to an infected individual [22] .

However, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) are more severe viral respiratory diseases caused by MERS-CoV and SARS-CoV, respectively. SARS was first identified in Guangdong (China) in 2002 and rapidly swept across the globe, resulting in the deaths of 774 people (the fatality rate reached 9.6%) [23, 24] . Patients with SARS were the most important source of infection, while those in the incubation and recovery periods were not infectious. The emergence of MERS was first reported in Saudi Arabia and then spread to other countries with a high fatality rate of 37% globally [25, 26] . Both MERS-CoV and SARS-CoV have originated in bats before spreading to an intermediate animal host and later human [27] [28] [29] . MERS-CoV has limited capacity for person-to-person transmission. The single-humped camel is a major intermediate host of MERS-CoV and is an important source of infection for humans. Similar to these two CoVs, SARS-CoV-2 predominantly attacks the lower respiratory tract, thus leading to viral pneumonia. Besides, it may also cause damage to the gastrointestinal tract, kidney, heart, liver, and/or central nervous system, thereby resulting in multiple organ dysfunction. The fatality rate of COVID-19 is currently estimated at < 4%. This indicates that the new CoV has lower fatality rate compared to MERS-CoV and SARS-CoV [30] , but is more contagious or transmissible than SARS-CoV [31] . protein is encoded by orf1a gene, which comprises of ten nsps (nsp1 to nsp10). The remaining structural proteins are encoded by different structural genes, namely, E (envelope), M (membrane), N (nucleocapsid) and S (spike).

The accessory genes are disseminated throughout the entire genome. Used with permission from Reference 35.

Copyright 2020 Cell Press.

Currently, the zoonotic sources of SARS-CoV-2 have not been verified; however, bats have been identified as the key reservoir via sequence-based analysis [32] .

Further homologous recombination analysis suggests that the receptor-binding S protein of SARS-CoV-2 is originated from a SARS-CoV (CoVZC45 or CoVZXC21) and a previously unidentified β-CoV [33] . Numerous observations have revealed that SARS-CoV-2 has person-to-person transmission capacity, through direct contact with an infected individual and specifically exposure to airborne SARS-CoV-2 particles and/or aerosols droplets expelled during breathing, coughing, sneezing and speaking [34] . These aerosols can enter the lungs by means of nasal or oral inhalation [34] .

Similar to other CoVs, the genome (about 29. Figure 3A delineates the structural domains of the construct used for protein expression. Figure 3B illustrates the 3D structures of prefusion SARS-CoV-2 spike ectodomain at 3.5 Å resolution, with one receptor-binding domain (RBD) in the up conformation and two RBDs in the down conformations [36] . The spike protein is composed of 2 functional subunits, namely, S1 and S2, which play an essential role in mediating the attachment of viral proteins to the host cell surface. S1 subunit is involved in the binding to a host-cell receptor, while S2 subunit is associated with the fusion between the viral membrane and the host-cell membrane [37] [38] [39] . The binding of S1 subunit to a host-cell receptor can destabilize the prefusion trimer, which in turn sheds the subunit and converts S2 subunit into a rigid post-fusion structure [17, 40] .

The RBD of S1 subunit displays an intrinsic hinge-like conformational movement as a means to bind to the host-cell receptor [36] . The two states of S1 subunit are characterized by the "up" and "down" conformations, which correspond to the receptor-accessible (less stable) and receptor-inaccessible states, respectively [36] .

The overall structure of SARS-CoV-2 S protein is comparable to that of SARS-CoV S protein, but a key difference between these two structures is the RBD locations at the J o u r n a l P r e -p r o o f ERGIC, ER-Golgi intermediate compartment [34] . Used with permission from Reference 34. Copyright 2020

Elsevier.

"down" conformation [36] . Thus, understanding the structural and functional properties of S protein may contribute to the development of new vaccine, therapeutic antibodies, and/or diagnostic tools.

The entry mechanism of CoVs is closely related to cellular proteases that cleave the S protein and allows it to undergo conformational changes [41] . The residue 394 (glutamine) in SARS-CoV-2 RBD can bind to the residue 31 (lysine) in human angiotensin-converting enzyme 2 (hACE2) receptor [42] . The entry processes of SARS-CoV-2 pathogen, including attachment, penetration, uncoating, replication, assembly and virion release, are described in Figure 4 [34] .

Fast and accurate diagnostic tests are needed to confirm COVID-19 infection, trace its origin, and suppress its transmission [43, 44] . The current diagnostic strategies for COVID-19 include both clinical and laboratory diagnosis.

J o u r n a l P r e -p r o o f

The symptoms of COVID-19 patients may develop gradually over one week or longer, first with mild symptoms, and then (in some cases) progress to dyspnea and even shock [30] . Common symptoms at disease onset are fever (98%), cough (76%), and fatigue or myalgia (44%); while less-common symptoms are sputum production (28%), headache (8%), hemoptysis (5%), and diarrhea (3%) [30] . Guan et al. [45] investigated the clinical features of COVID-19 patients by extracting the data of 1099 cases with laboratory-confirmed COVID-19 from 552 hospitals. Patients' median age was 47 years and the median incubation period was estimated at four days. Their most common symptom was fever, followed by cough (67.8%), whereas their least common symptoms were vomiting or nausea (5.0%) and diarrhea (3.8%). Moreover, Zhou and co-workers [46] assessed the clinical features of 191 patients with COVID-19. Approximately half of these patients had comorbidities, of which hypertension, diabetes and coronary heart disease were the most frequent.

Multivariable regression indicated the increased risk of in-hospital mortality was probably attributed to the older age.

The main method currently used to clinically diagnose COVID-19 is chest imaging, including chest X-ray and computed tomography (CT) scans. This method is also essential for diagnosing pneumonia and assessing its severity. Most patients with COVID-19 have abnormalities in chest imaging, usually with bilateral lung involvement, ranging from a ground-glass shadow at the recovery stage in patients with mild symptoms to a consolidation of lung lobes in patients with severe symptoms [47] [48] [49] [50] .

Chest X-ray examination typically shows interstitial alterations and multiple patchy shadows [30] , which are remarkable in the lung periphery [50] of pneumonia cases at the early stages. Patients with severe symptoms may present with multiple ground-glass opacities (GGOs), infiltrative shadows and pulmonary consolidation, together with pleural effusions [9] . Chest CT images ( Overall, CT scans seem to be more sensitive [52] and clearer than X-ray examinations for the diagnosis of COVID-19, but normal CT manifestations may not able to distinguish COVID-19 [53] . An investigation of the CT scans of COVID-19 patients (n = 21) revealed that three (14%) patients presented with normal CT scans, twelve (57%) presented with GGOs only, and six (29%) presented with GGOs and consolidation [54] . Another study of CT scans found pure GGOs in 77% of cases, GGOs with interlobular and/or interstitial septal thickening in 75% of cases, and GGOs with consolidation in 59% of cases [55] . Furthermore, the GGOs were bilateral in 88% of cases, involved the posterior lungs in 82% of cases, and the peripheral lungs in 85% of cases [55] . The imaging characteristics of COVID-19 patients were comparable to those infected with MERS or SARS, which is not surprising since they all belong to CoVs.

J o u r n a l P r e -p r o o f Table 1 List of primer/probe sets used for real-time RT-PCR assay. a BBQ, blackberry quencher; FAM, 6-carboxyfluorescein; M is A/C; R is G/A; S is G/C; W is A/T. b Optimized concentration of each primer/probe (nM) in the final reaction mixture [64] . Used with permission from Reference 64. Copyright 2020 European Centre for Disease Prevention and Control.

Primer sequence alignment and primer/probe design, and (ii) optimization and validation of RT-PCR assays [12] Through analysis of the related SARS genome sequences [61] [62] [63] , Corman et al.

[64] designed various primer/probe sets for detecting SARS-CoV (Table 1) SARS-CoV and an extra probe that only interacts with SARS-CoV-2. After designing primer/probe sets, the next step is to optimize assay conditions, such as reaction time, temperature and reagent conditions, followed by PCR amplification [65] . Laboratory testing that involves oropharyngeal and nasopharyngeal swab tests have become a standard procedure for the diagnosis of patients infected with COVID-19 based on the latest diagnostic criteria reported by the China National Health Commission.

The because the antibodies formed in response to viral proteins can provide a large window of opportunity [12] . Research on serology testing for COVID-19 has been recently undertaken by Zhou et al. [66] . The authors analyzed immunoglobulin G (IgG) and immunoglobulin M (IgM) in the serum samples of COVID-19 patients using an ELISA kit. Rp3 nucleocapsid protein is employed as an antigen, which has more than 90% amino acid identity to other related coronaviruses. They found that the positive rate of IgM was increased from 50% to 81%, while that of IgG was increased from 81% to 100%. Protein testing is beneficial to the diagnosis of COVID-19 after recovery, as opposed to nucleic acid testing. This allows clinicians to trace both infected and recovered cases in order to estimate the accumulated number of SARS-CoV-2 infections.

In the absence of laboratory infrastructure, point-of-care testing can be applied to diagnose patients more simply and quickly. A typical detection [12] uses a paper-like membrane strip that is coated with 2 lines. One line is conjugated with antibody-gold nanoparticles and another line captures antibodies. The patient's sample is dropped onto the membrane, and the targets are drawn up by capillary action into all the strips.

When the sample moves along the 1 st line, the proteins (antigens) may bind to antibody-gold nanoparticle conjugates, and the resulting complex will flow to and fuse with the membrane. When the complex reaches the 2 nd line, the complex is captured by the immobilized antibodies, and a blue or red line is visualized. The dispersed gold nanoparticle is red in color, while the aggregated gold nanoparticle is blue because of the coupling of the plasmon band. Unfortunately, a major obstacle for this test is the need to improve its sensitivity.

Another strategy to be used at the point-of-care is fluorescence-based biosensors.

Elledge et al. [67] developed the split luciferase antibody biosensors for a fast and low-cost detection of antibodies in whole blood, plasma, serum, and saliva. This point-of-care strategy, which obtained quantitative results within 5 minutes, greatly J o u r n a l P r e -p r o o f reduced the complexity and improved the scalability of COVID-19 diagnostic testing.

Point-of-care testing can serve as inexpensive, easy-to-use, handheld technique for diagnosing COVID-19 patients at areas outside a centralized facility, such as community centers, in order to reduce the burden of COVID-19 on clinical laboratories.

Currently, no specific anti-SARS-CoV-2 agent has been approved for treating COVID-19 patients. With only in vitro findings (for the SARS-CoV-2 and/or related viruses) and a lack of clinical experiences, several antiviral agents have been used under the "compassionate use" principle in the United States as they undergo testing in clinical trials.

Lopinavir and ritonavir have been approved by the Food and Drug Administration (FDA) for treating human immunodeficiency virus (HIV) infection [68, 69] . The agents have also been used in the empirical treatment of SARS [70] , and they are currently under study for the treatment of MERS [71] because lopinavir is a promising agent that suppresses the protease activities of CoVs in vitro. In China, these two antiviral agents have been used to treat some COVID-19 patients in concomitant with alpha interferon [72] . Han and co-workers [73] reported a case study of a 47-year-old man with a 1-week history of cough, fever, and bosom frowsty. such as cough with production of phlegm/mucus, runny or stuffy nose, fatigue and vertigo were considerably alleviated. Due to the repeated negative testing results on days six and seven and in addition to the partial absorption of lung lesions, the patient was no longer infectious and discharged from hospital on day 10, suggesting that the treatment strategy could be effective. A recent review [74] found that the anti-CoV effect of lopinavir/ritonavir combination therapy mainly occurred with early treatment window and included the reduction of patient fatality and glucocorticoid administration. However, if the ideal window was missed, the treatment might have no significant effects on patient outcomes. Therefore, further studies that explore the clinical effects of the early use of lopinavir/ritonavir combination therapy for treating SARS-CoV-2 pneumonia are needed.

Remdesivir, a monophosphoramidate prodrug of C-adenosine nucleoside analog, can be incorporated into viral RNA chains and thereby initiating the premature termination of RNA replication [75] . It displays a significant anti-CoV activity in vitro [75] . Previous studies [76] [77] [78] showed that remdesivir could inhibit the replication of SARS-CoV, MERS-CoV, and bat CoV strains in primary human airway epithelial cells and regulate cell entry through hACE2 receptor. Remdesivir acts during early-stage infection and dose dependently reduces RNA levels, which parallels a decrease in virus titers [79] . Remdesivir displays an EC 90 (90% effective concentration) value of 1.76 μM towards SARS-CoV-2 in Vero E6 cells, indicating that it is effective in non-human primates [80] . Besides, it is noted that SARS-CoV-2

requires RdRp gene to replicate, which can be covalently bound to remdesivir and hence terminating chain elongation [81] . Moreover, remdesivir also suppresses virus infection in human liver cancer Huh-7 cells, a cell line that is susceptible to SARS-CoV-2 [80] . Furthermore, remdesivir has been given on a compassionate use basis to COVID-19 patients [82] , and the results indicated that a 10-day course of the antiviral drug (200 mg on day 1, followed by 100 mg daily for 9 days) might exhibit potential clinical benefit for these patients.

Chloroquine is a potent broad-spectrum antiviral agent, which is commonly utilized as an autoimmune disease or anti-malarial agent [83] [84] [85] . Chloroquine may stop a virus infection by elevating the endosomal pH necessary for virus-cell fusion and disrupting the terminal glycosylation of hACE2 receptor [86] . Recent work has shown that chloroquine inhibits SARS-CoV-2 infection at entry and post-entry stages in a Vero E6 cell line [80] . After oral administration, chloroquine is distributed throughout the body, especially in the lungs. Apart from its antiviral activity, chloroquine also exhibits immunomodulatory activities, which in turn lead to a synergistic enhancement of its antiviral effect in vivo [80] . Chloroquine has been considered as a potential drug for the treatment and prevention of COVID-19 pneumonia [87, 88] .

However, a recent study has found that chloroquine is ineffective for the treatment of COVID-19 [89] . Given the controversy about the effectiveness of this antiviral agent, it is important to determine whether chloroquine has potential applicability for SARS-CoV-2 treatment and prevention.

Arbidol is a broad-spectrum antiviral agent that blocks influenza A and B viruses by inhibiting virus-cell membrane fusion [90] . Low-level evidence shows that arbidol taken alone or concomitantly with other antiviral drugs produces therapeutic benefits for COVID-19 pneumonia [91] [92] [93] . In China, many randomized control trials are currently underway to assess the efficacy of arbidol on COVID-19 pneumonia. Zhang J o u r n a l P r e -p r o o f

Immunity-based therapy, including convalescent plasma therapy and immunoglobulin therapy, is also an important strategy in the treatment of COVID- 19 

The S protein structures of SARS-CoV-2 have been identified previously. University has successfully established an oral SARS-CoV-2 vaccine, which applies spike protein as the target and Saccharomyces cerevisiae as the carrier [58] .

Currently, SARS-CoV-2 has spread to more than 240 countries worldwide, which causes illness ranging from the common cold to lung pneumonia, making it a very serious public-health threat. From the initial outbreak of COVID-19 to now (13 August, 2020), the United States has greatly surpassed China as the country with the largest number of confirmed COVID-19 cases globally. Based on a WHO report [8] , 

The authors declare that there are no conflicts of interest.

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase

Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes

Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

The SARS-CoV-2 outbreak: What we know

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

Diagnosing COVID-19: the disease and tools for detection

Reducing mortality from 2019-nCoV: host-directed therapies should be an option

COVID-19: Immunopathology and its implications for therapy

The structure and functions of coronavirus genomic 3' and 5' ends

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus, Microbiol

Coronaviruses post-SARS: update on replication and pathogenesis

The molecular biology of coronaviruses

Coronavirus disease 2019 (COVID-19): current status and future perspective

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A decade after SARS: strategies for controlling emerging coronaviruses

Middle East respiratory syndrome

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study

SARS and MERS: recent insights into emerging coronaviruses

Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond

Clinical features of patients infected with 2019 novel coronavirus in

An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Prefusion structure of a human coronavirus spike protein

Unexpected receptor functional mimicry elucidates activation of coronavirus fusion

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS

Molecular immune pathogenesis and diagnosis of COVID-19

Quantitative computed tomography analysis for stratifying the severity of Coronavirus Disease

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

A novel coronavirus from patients with pneumonia in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

3D CT of novel coronavirus (COVID-19) pneumonia

Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea

Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Emerging 2019 novel coronavirus (2019-nCoV) pneumonia

Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)

Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses

The epidemiology, diagnosis and treatment of COVID-19

Quantitative RT-PCR: pitfalls and potential

Broadly reactive and highly sensitive assay for norwalk-like viruses based on real-time quantitative reverse transcription-PCR

Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

Specific detection by real-time reverse-transcription PCR assays of a novel avian influenza A(H7N9) strain associated with human spillover infections in China

Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Real-time PCR for mRNA quantitation

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection

Lopinavir/ritonavir: a review of its use in the management of HIV infection

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019

The possibility of using lopinave/litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Compassionate use of remdesivir for patients with severe COVID-19

New insights into the antiviral effects of chloroquine

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Polycentric collaborative group of chloroquine phosphate in the treatment of new coronavirus pneumonia (Department of Science and Technology of Guangdong Province and Health Committee of Guangdong Province), Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia

Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report

Arbidol: a broad-spectrum antiviral compound that blocks viral eusion

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Potential of Arbidol for post-exposure prophylaxis of COVID-19 transmission: A preliminary report of a retrospective cohort study

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Convalescent plasma as a potential therapy for COVID-19

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

High-dose intravenous immunoglobulin as a terapeutic option for deteriorating patients with coronavirus disease

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

Development of an inactivated vaccine candidate for SARS-CoV-2

We first introduce the systematics of coronaviruses (CoVs) and the structural characteristics of SARS-CoV-2

We focused on the current developments in diagnostic strategies for COVID-19, including clinical diagnosis and laboratory diagnosis

Finally, we discuss the mainly potential treatments for COVID-19, including antiviral agents and vaccines

We are grateful for the financial support from the National Natural Science